Cambridge researchers express skepticism about the effectiveness of new amyloid immunotherapy drugs in significantly reducing Alzheimer’s disease impact, citing challenges such as small effect sizes, high costs, and limited patient eligibility. Credit: SciTechDaily.com
Researchers question the impact of amyloid immunotherapy on



















Discussion about this post